Semler Scientific (SMLR) Registration Filing summary

Company overview and business model

• Provides technology solutions to improve clinical effectiveness and efficiency for healthcare providers, focusing on products for chronic disease evaluation and treatment.

• Flagship product QuantaFlo is FDA-cleared for measuring arterial blood flow to aid in diagnosing cardiovascular diseases, with ongoing efforts to expand its indications.

• Recently adopted bitcoin as its primary treasury reserve asset, with significant purchases made in 2024.

Financial performance and metrics

• As of June 30, 2024, held approximately 877 bitcoins with a fair value of $54.9 million, reflecting a $5.1 million cumulative reduction in fair value since acquisition.

• The original cost basis for bitcoin holdings was $60.0 million.

• Stock price has been volatile, ranging from $21.03 to $51.54 per share in 2024.

Use of proceeds and capital allocation

• Net proceeds from offerings are intended primarily for general corporate purposes, including working capital, R&D, capital expenditures, potential acquisitions, and notably, further acquisition of bitcoin.

• Management retains broad discretion over allocation of proceeds.